AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer

Study ID
NCT01182246

Study type
Interventional

Study phase
Phase 1/Phase 2

Study status
Unknown status

Trial Acronym

Trial Summary

The purpose of this study is to assess the effect and safety of AXP107-11 alone, and in combination with gemcitabine standard therapy, in patients with advanced or metastatic cancer of the pancreas. The safety, pharmacokinetics and efficacy of AXP107-11 in these patients will also be studied.

More informations

Trial Starting Date

Nov 30,2010

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit